Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.2020.19925 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.
Aging Clin Exp Res
January 2025
Department of Spine Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, 710054, Shaanxi, China.
Objective: This study aims to analyze adverse drug events (ADE) related to romosozumab from the second quarter of 2019 to the third quarter of 2023 from FAERS database.
Methods: The ADE data related to romosozumab from 2019 Q2 to 2023 Q3 were collected. After data normalization, four signal strength quantification algorithms were used: ROR (Reporting Odds Ratios), PRR (Proportional Reporting Ratios), BCPNN (Bayesian Confidence Propagation Neural Network), and EBGM (Empirical Bayesian Geometric Mean).
Responses to the 2022 Infant Formula Shortage in the US by Race and Ethnicity.
J Nutr Educ Behav
January 2025
Economic Research Service, US Department of Agriculture.
Objective: Describe experiences of, and responses to, 2022 infant formula shortages among households with infants aged up to 18 months by race/ethnicity using Household Pulse Survey data.
Methods: Outcomes included whether households were affected by shortages and, if so, 3 nonmutually exclusive response categories (increased breastmilk, obtained formula atypically, and disruptive coping [disruptions to breastmilk and/or formula]) and 1 mutually exclusive response category (solely disruptive coping). Unadjusted shares reporting each were compared using t tests.
Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
Diabetes Obes Metab
January 2025
Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
Aims: To examine the cardiovascular safety of combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with aspirin in individuals with obesity, both with and without type 2 diabetes (T2D).
Materials And Methods: This propensity score matched cohort study analysed data from 2 946 579 individuals with obesity, with and without T2D, using the TriNetX US and Global dataset. Participants were categorized into four matched groups: those receiving GLP-1 RA plus aspirin versus those receiving GLP-1 RA alone, for both diabetic and non-diabetic individuals.
Occult collision tumor of the gastroesophageal junction comprising adenocarcinomas with distinct molecular profiles.
Cancer Genet
January 2025
Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; Rutgers Cancer Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Collision tumors, characterized by the coexistence of two unique neoplasms in close approximation, are rare and pose diagnostic challenges. This is particularly true when the unique neoplasms are of the same histologic type. Here we report such a case where comprehensive tumor profiling by next generation sequencing (NGS) as well as immunohistochemistry revealed two independent adenocarcinomas comprising what was initially diagnosed as a single adenocarcinoma of the gastroesophageal (GEJ) junction.
View Article and Find Full Text PDFSpin Class Spins Unexpected Diagnosis.
J Neuroophthalmol
November 2024
Atrium Wake Forest Baptist Health (FMdlC); Wake Forest School of Medicine (CT); Atrium Wake Forest Baptist Health (TM), Winston Salem, North Carolina.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!